- Home
- DOW vs ILMN Comparison
DOW vs ILMN Comparison
Compare DOW & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DOW | ILMN |
|---|---|---|
| Founded | 1897 | 1998 |
| Country | United States | United States |
| Employees | 35700 | N/A |
| Industry | Major Chemicals | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.9B | 19.4B |
| IPO Year | 2018 | 2000 |
Fundamental Metrics
Financial Performance| Metric | DOW | ILMN |
|---|---|---|
| Price | $38.14 | $126.45 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 15 | 17 |
| Target Price | $39.13 | ★ $124.24 |
| AVG Volume (30 Days) | ★ 14.4M | 1.2M |
| Earning Date | 04-23-2026 | 04-30-2026 |
| Dividend Yield | ★ 3.67% | N/A |
| EPS Growth | N/A | ★ 170.87 |
| EPS | N/A | ★ 5.45 |
| Revenue | ★ $39,968,000,000.00 | $4,343,000,000.00 |
| Revenue This Year | $5.40 | $6.47 |
| Revenue Next Year | $2.33 | $5.58 |
| P/E Ratio | ★ N/A | $23.51 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $20.40 | $73.86 |
| 52 Week High | $42.74 | $155.53 |
Technical Indicators
Market Signals| Indicator | DOW | ILMN |
|---|---|---|
| Relative Strength Index (RSI) | 50.13 | 48.13 |
| Support Level | $35.37 | $116.02 |
| Resistance Level | $42.74 | $128.96 |
| Average True Range (ATR) | 1.52 | 4.75 |
| MACD | -0.33 | -0.34 |
| Stochastic Oscillator | 56.72 | 42.29 |
Price Performance
Historical ComparisonAbout DOW Dow Inc.
Dow Chemical is a diversified global chemicals producer, formed in 2019 as a result of the DowDuPont merger and subsequent separations. The firm is a leading producer of several chemicals, including polyethylene, ethylene oxide, and silicone rubber. Its products have numerous applications in both consumer and industrial end markets.
About ILMN Illumina Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.